Organisation › Details

AstraZeneca R&D Centre Beijing

	Start	2025-03-21 announced
	Group	AstraZeneca (Group)
	Industry	drug discovery
	Industry 2	drug development

	Region	Beijing (Peking)
	Country	China
	City	n. a. Beijing
		Address record changed: 2025-03-22

Basic data	Employees	n. a.


		Record changed: 2025-03-23

Picture biomindz TRON LSE Mainz Translation Cancer Immunotherapy 650x200px

More documents for AstraZeneca (Group)

[1] AstraZeneca plc. (3/21/25). "Press Release: AstraZeneca to Invest $2.5 Billion in New Global Strategic R&D Centre, Biotech Agreements and Manufacturing in Beijing"....
[2] AstraZeneca plc. (3/17/25). "Press Release: AstraZeneca Enters License Agreement with Alteogen for Subcutaneous Formulations of Multiple Oncology Assets"....
[3] FibroGen, Inc.. (2/20/25). "Press Release: FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million". San Francisco, CA....
[4] EsoBiotec SA. (1/8/24). "Press Release: EsoBiotec Doses First Patient in Investigator Initiated Trial of In Vivo BCMA CAR-T Candidate ESO-T01 for Multiple Myeloma". Mont-Saint-Guibert....
[5] EsoBiotec SA. (12/11/24). "Press Release: EsoBiotec Begins Clinical Trial of In Vivo BCMA CAR-T Candidate ESO-T01 for Multiple Myeloma". Mont-Saint-Guibert....
[6] Pinetree Therapeutics, Inc.. (7/23/24). "Press Release: Pinetree Therapeutics Announces Exclusive Option and Global License Agreement for Preclinical EGFR Degrader Candidate with AstraZeneca". Cambridge, MA....
[7] Huma Therapeutics Ltd.. (7/16/24). "Press Release: Huma Completes Series D with Total Financing of over $80m as It Launches Huma Cloud Platform with GenAI Integrations to Bring Digital First Care and Research to Everyone". London & New York, NY....
[8] Allorion Therapeutics Inc.. (1/2/24). "Press Release: Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca". Natick, MA....
[9] AstraZeneca plc. (12/26/23). "Press Release: AstraZeneca to Acquire Gracell, Furthering Cell Therapy Ambition across Oncology and Autoimmune Diseases"....
[10] Gracell Biotechnologies Inc.. (12/26/23). "Press Release: Gracell Biotechnologies to Be Acquired by AstraZeneca, furthering Cell Therapy Ambition across Oncology and Autoimmune Diseases". San Diego, CA, Suzhou & Shanghai....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]